The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Selecting fixed-duration bispecific regimens in FL and DLBCL: treatment burden vs disease control
Pallawi Torka, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses how treatment burden influences the selection of fixed-duration bispecific antibody regimens for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL), with patient preferences varying by disease setting. Dr Torka explains, that in DLBCL, time-limited therapy is often preferred given the goal of cure, whereas in FL, minimizing hospital visits is particularly important, especially for older adults. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so this is a very nuanced question because the answer may differ in different diseases, specifically lymphomas. For example, if we’re talking about diffuse large B-cell lymphoma, it’s a life-threatening malignancy and the goal is cure, in which case, yes, time-limited treatments are always preferable, but a patient who has seen three relapses of this lymphoma may not mind coming every so often for treatment as long as the disease is controlled, versus something like follicular lymphoma, which is what patients live with for decades, and their quality of life is much more important, not just disease control and complete response...
Yeah, so this is a very nuanced question because the answer may differ in different diseases, specifically lymphomas. For example, if we’re talking about diffuse large B-cell lymphoma, it’s a life-threatening malignancy and the goal is cure, in which case, yes, time-limited treatments are always preferable, but a patient who has seen three relapses of this lymphoma may not mind coming every so often for treatment as long as the disease is controlled, versus something like follicular lymphoma, which is what patients live with for decades, and their quality of life is much more important, not just disease control and complete response. In older adults, this phenomenon is amplified because in general, their time is limited and for them, they need caregivers to bring them to appointments. So if we can reduce the number of appointments in a month and also reduce the amount of time they need, that’s really, really beneficial for them. And that’s what we found in the study is that’s what everyone likes: less time with the doctors, less time in the hospital.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
